Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
01/12/2018 01/15/2018 01/16/2018 01/17/2018 01/18/2018 Date
85.3(c) 85.5(c) 85.8(c) 85.75(c) 87.05 Last
120 254 71 889 114 486 112 005 117 658 Volume
-0.29% +0.23% +0.35% -0.06% +1.52% Change
More quotes
Financials (€)
Sales 2017 60,3 M
EBIT 2017 -47,0 M
Net income 2017 -66,0 M
Finance 2017 273 M
Yield 2017 -
Sales 2018 53,6 M
EBIT 2018 -58,4 M
Net income 2018 -66,7 M
Finance 2018 221 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 37,3x
EV / Sales2018 43,0x
Capitalization 2 523 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics and research applications.It operates through the following segments: Partnered Discovery and Proprietary Development.The Partnered Discovery segment involves technologies for the generation of human antibody... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
2017 MORPHOSYS AG : Release according to Article 26a of the WpHG [the German Securiti..
2017 MORPHOSYS : to Present at Upcoming Investor Conferences
2017 MORPHOSYS : to Present at Upcoming Investor Conferences
2017 MORPHOSYS : to Present at Upcoming Investor Conferences
2017 MORPHOSYS AG : Release according to Article 26, Section 1 of the WpHG [the Germa..
2017 MORPHOSYS : Presents Clinical Data on MOR208 plus Lenalidomide in Aggressive Lym..
2017 MORPHOSYS AG : Preliminary announcement of the publication of financial reports ..
2017 MORPHOSYS AG : Preliminary announcement of the publication of quarterly reports ..
2017 MORPHOSYS AG : Corporate Calendar 2018
2017 MORPHOSYS AG : Corporate Calendar 2018
More news
Sector news : Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/15MorphoSys's buy rating reiterated at JPMorgan Chase & Co..  
01/08Simon Moroney resigns as Munster GAA chief
7
01/04MorphoSys given €97.00 PT by JPMorgan Chase & Co.. buy rating.  
2017MorphoSys AG: Release according to Article 26a of the WpHG [the German Securi.. 
2017MorphoSys AG: Release according to Article 26a of the WpHG [the German Securi.. 
More tweets
Qtime:42
News from SeekingAlpha
01/10 Morphosys (MPSYY) Presents At 36th Annual J.P. Morgan Healthcare Conference -..
2017 MORPHOSYS : Partnered Drug Development Growth Is Its Key Value Driver
2017 Morphosys (MPSYY) Conference Call (L-MIND Data) - Slideshow
2017 WEEK IN REVIEW : Walgreens Boots Alliance Spends $420 Million For China Pharmacy..
2017 Morphosys' (MPSYF) CEO Simon Moroney on Q3 2017 Results - Earnings Call Trans..
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 83,5 €
Spread / Average Target -2,7%
EPS Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Günter Wellnhofer Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG11.97%3 091
CELLTRION, INC.--.--%40 725
IQVIA HOLDINGS INC2.07%20 784
LONZA GROUP2.47%20 682
INCYTE CORPORATION-3.23%19 342
ALNYLAM PHARMACEUTICALS, INC.-1.90%12 256